Introduction: Multiple sclerosis (MS) is a chronic autoimmune and demyelinating disease of central nervous system (CNS) leading to progressive function loss. Besides infiltration of peripheral immune cells into CNS subsequent to neuroinflammation, the accumulation of extracellular matrix (ECM) elements, produced by brain barrier cells, in the enlarged perivascular spaces contributes to the pathophysiology. In this study, we aimed to develop an in-vitro model of MS to investigate fibrosis triggered by sera or cerebrospinal fluid (CSF) from MS patients and evaluate the response of blood-brain barrier (BBB) cells to this model.
Methods: Human brain vascular pericytes, endothelial cells and normal human astrocytes were cultured and exposed to a cytokine reference control (Transforming growth factor beta 1 (TGF-β1)), healthy human sera, and sera/CSF from treatment naïve relapsing-remitting MS patients with the appropriate dilution dose. The pericytes cell proliferation were evaluated by xCELLigence, while the collagen and fibronectin expressions of BBB cells, and pericyte myofibroblastic transformation were analyzed with immunocytochemistry.
Results: TGF-β1 induced fibrosis, characterized by fibronectin overexpression, specifically in pericyte cultures. Furthermore, incubation of pericytes with MS serum but not CSF led to a more robust fibrotic response (fibronectin/collagen overexpression), myofibroblastic transformation as well as increased proliferation. Fibronectin overexpression was also detected in endothelial cell culture with MS serum. Glial fibrillary acidic protein (GFAP) expression is increased, but fibrotic markers are decreased in cultured astrocytes with MS serum.
Conclusion: Pericytes, among BBB-forming cells, were identified as key contributors to fibrosis in response to MS serum. MS-serum-induced in vitro models are promising for studying the individualized tendencies of patients and may be a new approach for high-throughput screening of potential treatment agents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877379 | PMC |
| http://dx.doi.org/10.29399/npa.28791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
J Pharmacol Exp Ther
February 2025
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pulmonary fibrosis encompasses different chronic interstitial lung diseases, and the predominant form, idiopathic pulmonary fibrosis, remains to have a poor prognosis despite 2 approved therapies. Although the exact pathobiological mechanisms are still incompletely understood, epithelial injury and aberrant wound healing responses contribute to the gradual change in lung architecture and functional impairment. Lysophosphatidic acid (LPA)-induced lysophosphatidic receptor 1 (LPA1) signaling was proposed to be a driver of lung fibrosis, and LPA1 antagonists have shown promising antifibrotic profiles in early clinical development.
View Article and Find Full Text PDFY chromosome-linked UTY modulates sex differences in valvular fibroblast methylation in response to nanoscale extracellular matrix cues.
Sci Adv
March 2025
Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.
Aortic valve stenosis (AVS) is a progressive disease, wherein males more often develop valve calcification relative to females that develop valve fibrosis. Valvular interstitial cells (VICs) aberrantly activate to myofibroblasts during AVS, driving the fibrotic valve phenotype in females. Myofibroblasts further differentiate into osteoblast-like cells and produce calcium nanoparticles, driving valve calcification in males.
View Article and Find Full Text PDFFAP-catalyzed in situ self-assembly of magnetic resonance imaging probe for early and precise staging of liver fibrosis.
Sci Adv
March 2025
Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200065, China.
Liver fibrosis is an inevitable stage in the progression of most chronic liver diseases. Early diagnosis and treatment of liver fibrosis are crucial for effectively managing chronic liver conditions. However, there lacks a noninvasive and sensitive imaging method capable of early assessing fibrosis activity.
View Article and Find Full Text PDFEndothelial Serotonin Receptor 1B Acts as a Mechanosensor to Drive Atherosclerosis.
Circ Res
March 2025
Faculty of Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong (M.J., H.D., C.W.L., Y.X., X.Y., Yu Huang).
Background: Atherosclerosis is characterized by the accumulation of fatty and fibrotic plaques, which preferentially develop at curvatures and branches along the arterial trees that are exposed to disturbed flow. However, the mechanisms by which endothelial cells sense disturbed flow are still unclear.
Methods: The partial carotid ligation mouse model was used to investigate disturbed flow-induced atherogenesis.
Trbp inhibits cardiac fibrosis through TGF-β pathway-mediated cross-talk between cardiomyocytes and fibroblasts.
Clin Sci (Lond)
March 2025
Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston MA 02115, U.S.A.
Cardiac remodeling in response to disease or tissue damage severely impairs heart function. Therefore, the description of the molecular mechanisms responsible is essential for the development of effective therapies. Trbp (Tarbp2) is a multifunctional RNA-binding protein that is essential during heart development, but its role in the adult heart and cardiac remodeling remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!